<!DOCTYPE html>
<html lang="" xml:lang="">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>What can be done to ensure LMICs are not left behind? |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</title>
  <meta name="description" content="<br />
97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</p>" />
  <meta name="generator" content="bookdown 0.24 and GitBook 2.6.7" />

  <meta property="og:title" content="What can be done to ensure LMICs are not left behind? |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  <meta property="og:type" content="book" />
  
  
  
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="What can be done to ensure LMICs are not left behind? |  97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES" />
  
  
  

<meta name="author" content="Russell E. Lewis, Associate Professor, Infectious Diseases, Department of Medical and Surgical Sciences" />


<meta name="date" content="2022-11-26" />

  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="what-are-the-current-strategies-to-incentive-antibiotic-development.html"/>

<script src="assets/header-attrs-2.11/header-attrs.js"></script>
<script src="assets/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="assets/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="assets/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="assets/anchor-sections-1.0.1/anchor-sections.css" rel="stylesheet" />
<script src="assets/anchor-sections-1.0.1/anchor-sections.js"></script>



<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="the-growing-crises-of-antibiotic-development.html"><a href="the-growing-crises-of-antibiotic-development.html"><i class="fa fa-check"></i>The growing crises of antibiotic development</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html"><i class="fa fa-check"></i>Why has antibiotic discovery faltered in recent years?</a>
<ul>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#scientific-challenges"><i class="fa fa-check"></i>Scientific challenges</a></li>
<li class="chapter" data-level="" data-path="why-has-antibiotic-discovery-faltered-in-recent-years.html"><a href="why-has-antibiotic-discovery-faltered-in-recent-years.html#antibiotic-regulatory-hurdles"><i class="fa fa-check"></i>Antibiotic regulatory hurdles</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html"><i class="fa fa-check"></i>What are the current strategies to incentive antibiotic development?</a></li>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-lmics-are-not-left-behind.html"><a href="what-can-be-done-to-ensure-lmics-are-not-left-behind.html"><i class="fa fa-check"></i>What can be done to ensure LMICs are not left behind?</a>
<ul>
<li class="chapter" data-level="" data-path="what-can-be-done-to-ensure-lmics-are-not-left-behind.html"><a href="what-can-be-done-to-ensure-lmics-are-not-left-behind.html#case-study-antibiotics-smart-use-asu-program-in-thailand"><i class="fa fa-check"></i>Case study: Antibiotics Smart Use (ASU) program in Thailand</a></li>
</ul></li>
</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./"><p><img src="images/logo.png" style="width:1in" /><br />
97039 - GLOBAL HEALTH, ANTIMICROBIAL DRUGS AND VACCINES</p></a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="what-can-be-done-to-ensure-lmics-are-not-left-behind" class="section level2 unnumbered">
<h2>What can be done to ensure LMICs are not left behind?</h2>
<p>individuals living in poverty are susceptible to infections and under poor living conditions (no access to basic sanitation facilities or health care) infections spread faster. Antibiotics, which may be available without prescription, are often used as substitutes for clean food, clean water, vaccines and diagnostics. Therefore, it will be impossible to address the challenges of antimicrobial resistance and lack of access to antibiotic therapy if other contributing factors are not addressed.</p>
<p>For countries where antibiotics can be accessed without a prescription, controlling antibiotic distribution should be highly prioritized. However, caution is warranted when a prescription system is introduced, especially when the demand for antibiotics is still high, as it can lead to unintentional consequences (such as the distribution of antibiotics on the black market) that are even harder to control. It is important to note that the overuse of antibiotics has become a social norm in many countries as it is influenced by the beliefs and attitudes of the individuals towards antibiotics as well as sociocultural factors, regardless of medical justifications.<span class="citation"><sup>9</sup></span></p>
<p>Meanwhile, social innovation for patients (such as a mirror toolkit for self-assessing whether their sore throat symptom is caused by a bacterial or a non-bacterial infection) enables them to make informed decisions and refrain from requesting antibiotics from prescribers/pharmacists, and eventually leads to reduction of unnecessary use of antibiotics.</p>
<div id="case-study-antibiotics-smart-use-asu-program-in-thailand" class="section level3 unnumbered">
<h3>Case study: Antibiotics Smart Use (ASU) program in Thailand</h3>
<p>The ASU program is an implementation research project comprised of three phases</p>
<ul>
<li>Implementation of behavior change interventions</li>
<li>Examination of the feasibility of scale up; and</li>
<li>Identification of mechanisms for sustainability</li>
</ul>
<p>The guiding principle of the ASU program is that antibiotics should not be used to treat non-bacterial infections. ASU started by trying to reduce unnecessary antibiotic use in patients with 3 conditions: upper respiratory tract infections, especially common colds with sore throat; acute diarrhea and simple wounds.</p>
<p>The program focused on simple measures, compatibility with the providers’ values, advantages with respect to current practice; performing testable interventions, and transparency.</p>
<p>In the beginning, ASU consisted of a network of researchers from Thailand’s Ministry of Public Health and pharmacists and doctors from Srinakharinwirot University and Chulalongkorn University.</p>
<ul>
<li><p><strong>In phase 1 (2007- 2008)</strong> they piloted educational and training reforms to improve prescribing in 10 hospitals and 87 primary health centres in one province. Antibiotic prescription, provider attitudes of effectiveness and knowledge of antibiotics, non-prescription rates in case of non-bacterial infections, and patient health and satisfaction were monitored.</p></li>
<li><p><strong>In</strong> <strong>phase 2</strong> <strong>(2008-2009)</strong> the same indicators were then used to scale up the program to three provinces and two hospital networks, counting to 44 hospitals and 621 primary health care centres.</p></li>
<li><p><strong>The 3rd phase</strong> <strong>(2010 – Present)</strong> is focusing on long-term sustainability and scale up of ASU – initially to 22 hospital networks in 15 provinces, and then subsequently across the entire country.</p></li>
</ul>
<table>
<colgroup>
<col width="11%" />
<col width="34%" />
<col width="29%" />
<col width="24%" />
</colgroup>
<thead>
<tr class="header">
<th align="left">Characteristics</th>
<th align="left">Phase 1<br />
(1 year)</th>
<th align="left">Phase 2<br />
(1 year, 3 months)</th>
<th align="left">Phase 3,<br />
transition period</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td align="left"><strong>Goals</strong></td>
<td align="left">Test effectiveness of ASU in changing antibiotic prescription behavior</td>
<td align="left">Test feasibility of scaling up ASU model</td>
<td align="left">Strengthen networks, assess scaling up mechanisms</td>
</tr>
<tr class="even">
<td align="left"><strong>Target</strong></td>
<td align="left">1 province</td>
<td align="left">3 provinces and 2 networks of public and private hospitals</td>
<td align="left">22 hospital networks in 15 provinces</td>
</tr>
<tr class="odd">
<td align="left"><strong>Funding<br />
agencies</strong></td>
<td align="left">WHO, Thai FDA</td>
<td align="left">HSRI, NHSO, Thai FDA</td>
<td align="left">DSMDC, Thai FDA</td>
</tr>
<tr class="even">
<td align="left"><strong>Coordinating<br />
agencies</strong></td>
<td align="left">Thai FDA</td>
<td align="left">Thai FDA</td>
<td align="left">DSMDC, Thai FDA, IHPP</td>
</tr>
<tr class="odd">
<td align="left"><strong>Budget spending</strong></td>
<td align="left">US$ 33,000</td>
<td align="left">US$ 73,000</td>
<td align="left">US$ 123,000</td>
</tr>
<tr class="even">
<td align="left"><strong>Spillover effect</strong></td>
<td align="left">No</td>
<td align="left">Yes</td>
<td align="left">Yes</td>
</tr>
</tbody>
</table>
<p>The program also had many simple but innovative community health interventions. For example, holding up a simple concave mirror to consumers trying to buy antibiotics for treating the common cold and cough was part of a new initiative in Thailand by community pharmacists to lower consumption of antibiotics.</p>
<center>
<p><img src="images/mirror.png" width="600" /></p>
<figcaption>
</center>
<p><strong>Figure 4. Mirror toolkit for patients to self-assess their sore throat symptoms in Thai Pharmacies</strong></p>
</figcaption>
<p>After completion of Phases I-2, the following results were noted:</p>
<ul>
<li><em>Positive effects on reducing antibiotic prescribing</em>. Antibiotic use was reduced by 18-46%</li>
<li>The percentage of patients who did not receive antibiotics increased by 29.1%, whereas there was no change in the control groups who were not involved in the ASU program</li>
<li><em>Patient health and satisfaction</em> <em>rates were high</em>, 96%-99.3% of patients surveyed who did not refeive antibiotics recovered and felt better within 7-10 days after their medical visits</li>
<li><em>Success in scaling up</em>. The number of hospitals adopting ASU increased from 44 hospitals (2008) to more than 600 hospitals (2010).</li>
</ul>
<p>The ASU project is having an impact beyond the borders of Thailand too and is now seen as a
model for replication in other parts of south-east Asia with interest elicited from as far away as
Africa and Latin America.<br />
Read more about the ASU project on the</p>
<div id="refs" class="references csl-bib-body" line-spacing="2">
<div class="csl-entry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Bush, K. &amp; Jacoby, G. A. <a href="https://doi.org/10.1128/AAC.01009-09">Updated <span>Functional Classification</span> of <span><span class="math inline">\(\beta\)</span></span>-<span>Lactamases</span></a>. <em>Antimicrobial Agents and Chemotherapy</em> <strong>54</strong>, 969–976 (2010).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Livermore, D. M. <em>et al.</em> <a href="https://doi.org/10.1093/jac/dkr262">Discovery research: The scientific challenge of finding new antibiotics</a>. <em>Journal of Antimicrobial Chemotherapy</em> <strong>66</strong>, 1941–1944 (2011).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Kållberg, C. <em>et al.</em> <a href="https://doi.org/10.1371/journal.pone.0205166">Introduction and geographic availability of new antibiotics approved between 1999 and 2014</a>. <em>PLOS ONE</em> <strong>13</strong>, e0205166 (2018).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Outterson, K., Orubu, E. S. F., Rex, J., Årdal, C. &amp; Zaman, M. H. Patient <span>Access</span> in 14 <span>High-Income Countries</span> to <span>New Antibacterials Approved</span> by the <span>US Food</span> and <span>Drug Administration</span>, <span>European Medicines Agency</span>, <span>Japanese Pharmaceuticals</span> and <span>Medical Devices Agency</span>, or <span>Health Canada</span>, 2010. <em>Clinical Infectious Diseases</em> ciab612 (2021) doi:<a href="https://doi.org/10.1093/cid/ciab612">10.1093/cid/ciab612</a>.</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Echols, R., Ariyasu, M. &amp; Nagata, T. D. <a href="https://doi.org/10.1093/cid/ciz829">Pathogen-focused <span>Clinical Development</span> to <span>Address Unmet Medical Need</span>: <span>Cefiderocol Targeting Carbapenem Resistance</span></a>. <em>Clinical Infectious Diseases</em> <strong>69</strong>, S559–S564 (2019).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Wouters, O. J., McKee, M. &amp; Luyten, J. <a href="https://doi.org/10.1001/jama.2020.1166">Estimated <span>Research</span> and <span>Development Investment Needed</span> to <span>Bring</span> a <span>New Medicine</span> to <span>Market</span>, 2009-2018</a>. <em>JAMA</em> <strong>323</strong>, 844–853 (2020).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Årdal, C. <em>et al.</em> <a href="https://doi.org/10.1038/s41579-019-0293-3">Antibiotic development  economic, regulatory and societal challenges</a>. <em>Nature Reviews Microbiology</em> <strong>18</strong>, 267–274 (2020).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Mullard, A. <a href="https://doi.org/10.1038/d41573-019-00085-w">Achaogen bankruptcy highlights antibacterial development woes</a>. <em>Nature Reviews. Drug Discovery</em> <strong>18</strong>, 411 (2019).</div>
</div>
<div class="csl-entry">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Do, N. T. T. <em>et al.</em> <a href="https://doi.org/10.1016/S2214-109X(21)00024-3">Community-based antibiotic access and use in six low-income and middle-income countries: A mixed-method approach</a>. <em>The Lancet Global Health</em> <strong>9</strong>, e610–e619 (2021).</div>
</div>
</div>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="what-are-the-current-strategies-to-incentive-antibiotic-development.html" class="navigation navigation-prev navigation-unique" aria-label="Previous page"><i class="fa fa-angle-left"></i></a>

    </div>
  </div>
<script src="assets/gitbook-2.6.7/js/app.min.js"></script>
<script src="assets/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="assets/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="assets/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": null,
"search": false,
"toc": {
"collapse": "subsection"
},
"toolbar": {
"position": "static"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
